HappycapyGuide

By Connie · Last reviewed: April 2026 — pricing & tools verified · AI-assisted, human-edited · This article contains affiliate links. We may earn a commission at no extra cost to you if you sign up through our links.

How to Use AI for a Rheumatology Practice in 2026: Biologic Prior-Auth, Step-Therapy Appeals, T2T Disease Activity, MIPS MVP MSK, and the Owner Scorecard

Published 2026-06-03 · 14 min read

TL;DR — rheumatology practice AI stack for 2026. Point AI at six bottlenecks: (1) new-patient + referral triage with red-flag screen for GCA, scleroderma renal crisis, and inflammatory myositis, (2) ambient-scribed rheumatology SOAP with auto-scored DAS28 / SDAI / CDAI / ASDAS / BASDAI / DAPSA / SLEDAI-2K / RAPID3, (3) biologic + JAK + ns-DMARD selection with ACR / EULAR / SPARTAN / GRAPPA guideline citations, (4) prior-auth narrative + step-therapy override appeal across 30+ state reform statutes, (5) T2T treat-to-target dashboard for every active patient, (6) MIPS MVP Advancing Care for MSK + AKS + Stark + Sunshine Act audit. Wrap it in a compliance floor: HIPAA + state AI-scribe consent (CA AB 3030, TX SB 815, IL HB 1806, UT HB 452), FDA Boxed Warning JAK 2021-2025, ACR / EULAR guidelines, MIPS MVP, AKS / Stark on infusion + 340B + buy-and-bill, FTC Endorsement Guides + Fake Reviews Rule. Target owner KPI: T2T documented at over 90 percent of visits, biologic PA approval rate above 85 percent, infusion-suite utilization above 80 percent, MIPS MVP score above 85, and a weekly 60-minute scorecard.

The 7-layer rheumatology AI stack (2026)

LayerExamplesOwner
EHR + rheumatology moduleEpic Rheumatology, Oracle Cerner Millennium, athenaOne Rheum, eClinicalWorks Rheum, NextGen Healthcare, Modernizing Medicine EMA Rheum, Nextech Rheum, RheumPACS, AdvancedMD, DrChronoCMO + practice manager
Ambient scribe + SOAPDeepScribe, Abridge, Suki Assistant, Nuance DAX Copilot, Heidi, Freed, Sunoh.ai, Nabla, Augmedix, Ambient.aiRheumatologist
Disease activity + PRORISE Registry (ACR), Bendcare RaaS, Patient IQ, Greenspace Health, Force Therapeutics, RAPID3 / MDHAQ smart-sets, BASDAI patient form, SLEDAI-2K calculatorNursing + MA
Imaging + lab AI overreadAidoc + Gleamer BoneView for radiograph, MSK ultrasound (GE LOGIQ E10, Philips EPIQ Elite, Samsung HS70A) + EULAR / OMERACT scoring, Rheumera AIRheumatologist
Prior-auth + appealCohere Health, CoverMyMeds, Glidian, Myndshft, Olive AI Authorize, SamaCare, SamaScribe, Office Ally, Availity, Waystar, Change HealthcarePractice manager + RN
Infusion-suite + 340BInfuSystem, Cerner Power Insight, Drug-Inventory Manager, 340B Health, Apexus, Verity Solutions, Macro Helix Sentinel, SectyrInfusion lead + compliance
Compliance + MIPS MVPCompliancy Group, Compliancy ERS, MDinteractive, Mingle Health, Healthmonix MIPSpro, RISE Registry MIPS, Sectyr Sunshine, ProPharma 340B auditCompliance officer

10 copy-paste prompts for rheumatology teams

1) New-patient + referral triage with red-flag screen

You are the rheumatology intake AI. From the referral note + patient questionnaire (RAPID3, MDHAQ, BASDAI patient form, SLEDAI-2K self-report) + recent labs + imaging, classify: - INFLAMMATORY_ARTHRITIS (RA, axSpA, PsA, JIA carryover, undifferentiated) - CONNECTIVE_TISSUE_DISEASE (SLE, Sjogren, scleroderma, MCTD, dermatomyositis, polymyositis, IBM) - VASCULITIS (GCA, ANCA-associated, IgA, Behcet, Takayasu, polyarteritis nodosa) - CRYSTAL (gout, CPPD, BCP) - NON-INFLAMMATORY (OA, fibromyalgia, regional pain, hypermobility) - OTHER (sarcoid, IgG4, amyloid, paraneoplastic) RED-FLAG: temporal headache + jaw claudication + visual change in age 50 and over (GCA, same-day hospital eval), new Raynaud + skin-tightening + ACEi-resistant hypertension (scleroderma renal crisis, ED), proximal weakness + dysphagia + elevated CK (myositis with esophageal involvement), drop in eGFR + active urine sediment + serositis (lupus nephritis flare), digital ischemia + livedo + new-onset HTN (vasculitis). For non-red-flag, capture: PROs (RAPID3, MDHAQ, BASDAI, BASFI, FACIT-Fatigue, EQ-5D), symptom timeline, prior DMARD / biologic / JAK history with reason for stop, comorbidities (CV, malignancy, infection, pregnancy, hepatitis, TB, MAC), insurance + pharmacy + infusion-suite eligibility. Schedule: same-day for red-flag, within 2 weeks for inflammatory or new diagnosis with active synovitis, within 4 weeks for established follow-up. Log in Epic / Cerner / athena / eCW / NextGen / EMA Rheum with auto-populated chief complaint, ROS, PMH, FH, SH, allergies, meds.

2) Ambient-scribed rheumatology SOAP with auto-scored disease activity

You are the ambient scribe. From the recorded encounter + intake PROs + tender / swollen joint count + recent labs + imaging, draft the rheumatology SOAP. Include: S: chief complaint, HPI with onset / quality / radiation / aggravating / alleviating, ROS by system, current meds + adherence, social hx, family hx O: vitals, focused MSK exam (28-joint count for RA, BASDAI for axSpA, PASI + nail + dactylitis + enthesitis for PsA, SLEDAI exam for lupus, MMT + skin / nail-fold capillary for myositis), labs (CRP, ESR, RF, anti-CCP, ANA, ENA panel, complement C3 / C4, dsDNA, ANCA, urinalysis with sediment, CK, aldolase), imaging (radiograph for erosions, MSK US for synovitis with PD signal + EULAR / OMERACT score, MRI for spine + SI joint inflammation, DXA for bone density) A: per-condition assessment with ICD-10 (M05.79 / M06.x / M45 / L40.5x / M32 / M35.0 / M33 / M30 / M10) + AUTO-CALCULATED disease activity score: - RA: DAS28-CRP, SDAI, CDAI with target low disease activity or remission per ACR / EULAR T2T - axSpA: ASDAS-CRP target less than 2.1, BASDAI target less than 4 - PsA: DAPSA target less than 14 (LDA) or less than 4 (remission), MDA, PASDAS - SLE: SLEDAI-2K, BILAG-2004, SLE-DAS, lupus low disease activity state (LLDAS) - Vasculitis: BVAS, VDI - Common: RAPID3, FACIT-Fatigue, EQ-5D P: medication change with rationale + dose + frequency + duration, monitoring labs at 4 / 8 / 12 weeks, vaccination plan (flu, pneumococcal PCV20 / PPSV23, RZV, hepB, HPV, COVID-19 per CDC + ACR Vaccine Recommendations), bone-health (DXA, Ca, vit D, FRAX, bisphosphonate / denosumab if indicated), infection screen (TB, HBV, HCV, HIV, VZV before biologic / JAK), pregnancy + lactation review for child-bearing potential, smoking cessation, return-to-work / disability paperwork. Output 1 page, structured headers, with auto-populated CPT (99213-99215 office, 99201-99205 new) + ICD-10 + modifier 25 for separate procedure (joint injection 20610, 20605, 20600). Verify clinician reviews + signs before transmission. Do not prescribe biologic / JAK without prior-auth + Boxed Warning + screening labs documented.

3) Biologic + JAK + ns-DMARD selection memo

You are the rheumatologist. For [PATIENT_ID] with active RA / axSpA / PsA / SLE / vasculitis / GCA / IIM, draft a 1-page therapy-selection memo: 1) Current diagnosis with ICD-10, disease activity score, and target (T2T) 2) Failed therapies + reason for stop (inefficacy by score, AE, contraindication) 3) Comorbidity grid: CV risk + ASCVD score, malignancy hx, infection (TB / HBV / HCV / HIV / VZV / MAC), CKD eGFR, hepatic, pregnancy + lactation, family-planning, vaccination status 4) Recommended next-line per ACR 2021 + 2023 RA Guideline / EULAR 2023 RA Update / ACR-SAA-SPARTAN 2019 axSpA / EULAR 2022 axSpA / GRAPPA 2021 PsA / ACR 2024 SLE Guideline / EULAR 2024 SLE Update / ACR 2021 GCA / EULAR 2022 GCA / ACR 2018 myositis with rationale: - csDMARD (MTX, SSZ, HCQ, LEF, AZA, MMF, CYC, tacrolimus, cyclosporine) - bDMARD: TNF (adalimumab, etanercept, infliximab, certolizumab, golimumab + biosimilars Hyrimoz, Cyltezo, Hadlima, Yusimry, Yuflyma, Inflectra, Renflexis, Avsola, Erelzi, Eticovo) - IL-6: tocilizumab (Actemra), sarilumab (Kevzara), Tyenne / Tofidence biosimilars - IL-17: secukinumab (Cosentyx), ixekizumab (Taltz), bimekizumab (Bimzelx) - IL-23: guselkumab (Tremfya), risankizumab (Skyrizi), tildrakizumab (Ilumya) - IL-12 / 23: ustekinumab (Stelara, Wezlana, Selarsdi, Imuldosa biosimilars), Pyzchiva - T-cell co-stim: abatacept (Orencia) - B-cell: rituximab (Rituxan + Ruxience, Truxima, Riabni biosimilars), ocrelizumab off-label - Anti-BAFF: belimumab (Benlysta) for SLE - Type I IFN: anifrolumab (Saphnelo) for SLE - C5: avacopan (Tavneos) for AAV - JAK: tofacitinib (Xeljanz), baricitinib (Olumiant), upadacitinib (Rinvoq) WITH FDA SEPTEMBER 2021 BOXED WARNING (CV death, MI, stroke, malignancy, thrombosis, mortality vs TNFi in age 50 and over with at least 1 CV risk factor) — document failed or contraindicated TNFi + shared-decision-making consent - PDE4: apremilast (Otezla) - GC + steroid-sparing strategy 5) Required pre-treatment workup: CBC, CMP, LFT, lipid panel, hepatitis B + C surface + core, HIV, TB (IGRA preferred over TST), VZV titer + zoster vaccination plan, pregnancy test, vaccination update (live vaccines BEFORE biologic / JAK) 6) Monitoring schedule per agent (CBC + LFT + lipid + viral every 3-6 months, more frequent for JAK / IL-6) 7) Patient counseling + shared decision making + BOXED WARNING discussion + signed consent form 8) Prior-auth narrative drafted (Prompt 4) Flag any contraindications + drug-drug interactions. Verify clinician signs.

4) Biologic prior-auth + step-therapy override appeal

You are the prior-auth specialist. Draft a payer-policy-aligned PA letter + step-therapy override appeal for [PATIENT_ID] requesting [DRUG_NAME] for [DIAGNOSIS]: 1) Patient demographics + insurance + PBM + plan type (commercial, MA, Medicaid managed, exchange, ERISA self-funded) 2) Diagnosis with ICD-10 + date of diagnosis + duration of disease 3) Disease activity at baseline + current with validated score (DAS28-CRP, ASDAS-CRP, DAPSA, SLEDAI-2K, BVAS, MMT-8) and target per T2T 4) Step therapy already tried (csDMARD MTX 25 mg weekly subq for 12 weeks with persistent moderate disease activity; or TNFi adalimumab 40 mg q2w for 16 weeks with secondary loss of response) with start / stop dates + reason for failure 5) Contraindications to alternative agents (heart failure NYHA III-IV for TNFi, demyelinating disease, malignancy, recurrent infection, latent TB pending treatment) 6) Requested agent + dose + frequency + duration + ICD-10 supporting 7) Guideline citation: ACR 2021 + 2023 RA Guideline conditional recommendation, EULAR 2023 RA Update, ACR-SAA-SPARTAN 2019 axSpA, EULAR 2022 axSpA, GRAPPA 2021 PsA, ACR 2024 SLE, EULAR 2024 SLE, ACR 2021 GCA, EULAR 2022 GCA, ACR 2018 myositis — quote the section + recommendation strength 8) Payer policy citation (Aetna 0341 RA, BCBS A1909 Biologic Therapy, Cigna 0307 Biologics, UHC 2023R0125B Inflammatory Arthritis, Humana medical-policy reference) 9) State step-therapy override statute citation if applicable: NY S762, CA SB 999, FL SB 530, TX HB 2099, IL HB 2189, NJ A536, MD HB 0566, OH SB 56, PA HB 225, WA HB 2257 + medically-appropriate-exemption clause + payer response window 10) For Medicare Advantage, cite CMS Final Rule 2024 + 2025 (90 CFR Part 422) + NCD compendium support + MAC LCD if applicable 11) For JAK request, ATTACH FDA Boxed Warning + failed-or-contraindicated TNFi documentation + signed shared-decision-making consent 12) Clinician signature + date Submit through CoverMyMeds / Glidian / Surescripts CompletEPA / Cohere Health / Olive AI Authorize / SamaCare. Track approval window per payer + escalate to peer-to-peer + state external review on denial.

5) Treat-to-target dashboard + visit-day flag

You are the rheumatology coordinator. From the active patient panel, build the daily T2T dashboard: 1) For each patient with appointment today, pull last disease activity score + target + delta vs prior 2) FLAG patients above target — drop into the visit-day medication-change discussion queue 3) FLAG patients with no documented score in 6 months — capture-now via portal pre-visit PRO (RAPID3, MDHAQ, BASDAI, RAPID-MDHAQ-FN) 4) FLAG patients with overdue labs (CBC, LFT, lipid panel, HBV reactivation screen, TB monitoring) per agent + monitoring schedule 5) FLAG patients with overdue imaging (radiograph erosions q1-2yr active RA, DXA q2yr post-GC, MSK US q3-6mo for synovitis monitoring) 6) FLAG patients with overdue vaccinations per ACR 2022 Vaccine Guideline + CDC ACIP (flu, pneumococcal PCV20 / PPSV23, RZV, hepB, COVID-19, HPV) 7) FLAG patients on JAK in age 50 and over without documented MACE / VTE risk discussion in 12 months 8) FLAG patients with biologic AR over 60 days 9) FLAG infusion-suite no-show or missed dose with rebook SMS (TCPA + state mini-TCPA + quiet hours 8am-9pm) 10) FLAG MIPS MVP MSK quality measures pending: RA Periodic Assessment (QID 177), Functional Status (QID 178), Tobacco Cessation, Influenza, Pneumococcal, BP screening Output the AM huddle list + per-provider visit-day card. Update RISE Registry + Bendcare RaaS + Patient IQ at end of day.

6) Infusion-suite + 340B + AKS + Stark audit

You are the compliance officer. Run the monthly infusion-suite + 340B + AKS + Stark audit: 1) Drug-acquisition cost per dose (Remicade, Actemra, Orencia, Rituxan, Simponi Aria, Cosentyx, biosimilars Inflectra / Renflexis / Avsola / Hyrimoz / Cyltezo / Hadlima / Tyenne / Tofidence / Wezlana / Selarsdi) reconciled against wholesaler invoice + GPO contract + manufacturer rebate 2) Buy-and-bill margin per drug + per encounter — flag any margin outside the trailing 12-month band by more than 2 SD 3) GPO + manufacturer rebate + speaker / consulting fee logged in the Sunshine Act register (Open Payments) — FY 2026 thresholds $13.46 single / $134.49 aggregate per recipient 4) In-office ancillary services exception to Stark (42 USC §1395nn) — same-building, supervised, billed under the group, ownership disclosure on file, financial-interest disclosure to patients per the OIG Special Advisory Bulletin 5) AKS Safe Harbor review (42 CFR §1001.952) — discount, GPO, employee, personal-services, referral-arrangements safe harbors with written-agreement + FMV 6) 340B-covered entity: contract-pharmacy diversion + duplicate-discount audit (HRSA 340B + Medicaid drug-rebate carve-out + state Medicaid carve-in / carve-out rule); ProPharma / Apexus / Verity / Macro Helix Sentinel / Sectyr 340B audit 7) Patient-assistance + co-pay coupon: no Medicare / Medicaid beneficiary steering (OIG Special Advisory 2014 + 2024 Update) 8) Infusion-suite labor + nursing ratio + chair-time + missed-dose rate + adverse-event log 9) Vendor BAA + EPCS audit + state pharmacy board compliance 10) Quarterly written report to managing partner + outside counsel Flag any item missing documentation. Refuse to sign off until cured.

7) HIPAA-safe recall + portal nudge

You are the patient-engagement coordinator. Draft HIPAA + 45 CFR §164.514 + minimum-necessary recall messages: - LAB_RECALL: "Time for your every-3-month lab work — please book within 7 days. — Capybara Rheumatology" - INFUSION_RECALL: "Your infusion is due [DATE]. Reply YES to confirm or call to reschedule. — Capybara Rheumatology" - VACCINATION_RECALL: "Per ACR + CDC, you are due for flu / pneumococcal / RZV / COVID. Please book at your next visit. — Capybara Rheumatology" - DXA_RECALL: "It has been 24 months since your last bone-density scan. Please call to schedule. — Capybara Rheumatology" - T2T_OUTREACH: "Your last disease activity score was above target. Please reply with your current pain / stiffness rating to help your provider prepare for your next visit. — Capybara Rheumatology" Do not include diagnosis, drug name, or PHI in the message body. Use TCPA + state mini-TCPA + quiet hours 8am-9pm + opt-out language. Honor opt-outs immediately. Include practice name + phone + address + state-board license # in the footer per state-board advertising rules. Log every recall + reply in Epic / Cerner / athena / eCW + RISE Registry.

8) Review reply (5-star + 1-3 star)

You are the practice manager. Draft review replies: - 5-STAR: thank by first name, reference one general practice value (compassionate care, evidence-based, prompt PA turnaround), invite future follow-up. Do NOT mention patient diagnosis, treatment, or PHI. Do NOT offer gift cards / discounts / cash for reviews (FTC Fake Reviews Rule 16 CFR 465 + $51,744/violation FY 2026). - 1-3 STAR: acknowledge the concern, do NOT confirm or deny patient identity, provide practice-manager direct line for offline resolution. Never reference any clinical detail publicly. Never confirm the reviewer is a patient (HIPAA disclosure trigger). Flag any review that references a specific drug, denial, or adverse event for medical-director review + risk-management notification. Do not respond on-platform until reviewed.

9) State-compliant ad + state-board + telerheum

You are the marketing lead. Draft ad copy variants for Google Search + GBP + Facebook + Instagram for [SERVICE_LINE] in [STATE]: 1) State medical board license # verbatim + ACR fellowship status if applicable 2) No "best rheumatologist in [city]" / "miracle cure for arthritis" / "guaranteed remission" — state medical-board advertising rules + FTC Act §5 UDAP 3) No before/after photos of patients without HIPAA-compliant written authorization (45 CFR §164.508) + material-connection disclosure (FTC Endorsement Guides 2023 + 2024-2025) 4) No fake-review incentives 5) ADA + accessibility (alt text, contrast, screen-reader) 6) Telerheum disclosure: state licensure + IMLC Interstate Medical Licensure Compact + DEA Telemedicine Rule + Ryan Haight + state controlled-substance e-Rx + in-person-evaluation exception per state 7) State AI-scribe + AI-use consent: CA AB 3030 (Jan 2025), TX SB 815 (Sep 2025), IL HB 1806 (Jan 2026), UT HB 452 AI Mental Health Policy Act, FSMB Model Policy on AI 8) State-board-approved disclaimer: "individual results vary" Output 3 headline variants + 3 body variants + 1 CTA + image-caption brief.

10) Owner monthly scorecard

Produce a 1-page owner monthly scorecard: - Volume: new-patient visits, follow-up visits, procedures (joint injection 20610 / 20605 / 20600, MSK US 76881 / 76882, DXA 77080), telerheum visits, infusion-suite encounters - Disease activity + T2T: percent of visits with documented score, percent at target, percent above target with medication change in last visit - PA + appeal: PA submitted, approved-on-first-pass, peer-to-peer count, state-external-review, average turnaround days - Infusion-suite: chair-time utilization, missed-dose rate, adverse-event count, biologic AR over 60 days - Compliance: AKS / Stark / Sunshine / 340B audit findings, MIPS MVP MSK score, RISE Registry submission status - Cash: revenue per visit, infusion-suite revenue per chair-day, gross margin per drug, AR aging 0-30 / 31-60 / 60 plus - People: open roles, NP / PA / RN ratio, ambient-scribe adoption rate, provider satisfaction - Customer: new reviews (5-star + sub-4 count), GBP rating trend, complaint count, no-show rate Flag the 3 highest-priority issues for the next month. No more.

Compliance floor (2026) — do not ship without these

60-day AI rollout for a 1-5 rheumatologist practice

  1. Days 1-5: EHR rheumatology module audit (Epic / Cerner / athena / eCW / NextGen / EMA Rheum). Ambient-scribe vendor selection (DeepScribe / Abridge / Suki / DAX / Heidi / Freed). BAA + state AI-scribe consent forms drafted and posted.
  2. Days 6-10: Intake + triage AI live (Prompt 1) with red-flag GCA / scleroderma renal crisis / lupus nephritis routing.
  3. Days 11-15: Ambient-scribed SOAP + auto-scored disease activity (Prompt 2) live. RAPID3 / MDHAQ / BASDAI / SLEDAI-2K patient PROs in portal.
  4. Days 16-20: Biologic + JAK + ns-DMARD selection memo template (Prompt 3) reviewed by senior partner + signed by all prescribers. JAK Boxed Warning consent form posted.
  5. Days 21-30: PA + step-therapy override appeal AI (Prompt 4) live in CoverMyMeds / Glidian / Cohere Health. State step-therapy reform language in template.
  6. Days 31-40: T2T daily dashboard (Prompt 5) live. RISE Registry submission set up. Infusion-suite + 340B + AKS / Stark audit (Prompt 6) calendared monthly.
  7. Days 41-50: HIPAA-safe recall (Prompt 7) and review-reply (Prompt 8) workflows live. State-compliant telerheum ad (Prompt 9) reviewed by state-medical-board counsel.
  8. Days 51-60: Owner monthly scorecard (Prompt 10) live. First MIPS MVP MSK + RISE quality submission. Compliance officer signs first quarterly Sunshine + 340B + AKS / Stark report.

8 mistakes that sink rheumatology AI projects

FAQ

Can AI write the biologic prior-authorization letter and the step-therapy override appeal?

AI can produce a strong first draft, but the rheumatologist must verify every clinical claim, citation, and dose — and sign. The standard letter cites the diagnosis with ICD-10 (M05/M06 RA, M45 axSpA, L40.5 PsA, M32 SLE, M35.0 Sjogren, M33 dermatomyositis, M30 GCA), prior step-therapy failures with drug name + dose + duration + reason for stop (inefficacy, AE, contraindication), disease activity score (DAS28-CRP, CDAI, SDAI, ASDAS-CRP, BASDAI, SLEDAI-2K, PsARC), the ACR / EULAR / SPARTAN / GRAPPA / GCA guideline citation supporting the requested agent, and the ERISA + state external-review pathway if denied. AI draws from MCG / InterQual / NCCN compendium / payer policy + CMS NCD / MAC LCD. Pair with Cohere Health / CoverMyMeds / Glidian / Myndshft / Olive AI Authorize / SamaCare / SamaScribe for end-to-end submission. The 2024-2026 step-therapy reform laws in 30+ states (NY S762, CA SB 999, FL SB 530, TX HB 2099, IL HB 2189, NJ A536, MD HB 0566, OH SB 56, PA HB 225, WA HB 2257) shorten payer response windows and create medically-appropriate exemptions — the appeal must reference the controlling state statute.

Where does the FDA Boxed Warning on JAK inhibitors fit into our prescribing workflow?

The FDA September 2021 Boxed Warning (updated 2022 + 2023 + reaffirmed 2024-2025) on JAK inhibitors (Xeljanz tofacitinib, Olumiant baricitinib, Rinvoq upadacitinib) covers serious heart-related events (MI, stroke, CV death), serious infections, malignancy, thrombosis, and mortality vs TNF inhibitors in patients age 50 and over with at least one CV risk factor. The compliance floor: (1) document failed or contraindicated TNF inhibitor before starting JAK in age 50 and over with CV risk, (2) capture written shared-decision-making consent that references the boxed warning, (3) baseline + ongoing monitoring (CBC, LFT, lipid panel, TB / HBV / VZV screen, MACE / VTE risk score), (4) state-specific consent forms where applicable, (5) prior-auth narrative cites the boxed warning AND the rationale for JAK over TNF / IL-6 / IL-17 / IL-23. AI can pre-populate the consent form, baseline lab order set, and PA narrative — but the prescriber signs and counsels.

How do we run treat-to-target (T2T) at scale across 200-2000 active patients?

T2T means measuring disease activity at every visit with a validated instrument (DAS28-CRP / SDAI / CDAI for RA, ASDAS / BASDAI / BASFI for axSpA, PsARC / DAPSA / MDA for PsA, SLEDAI-2K / BILAG / SLE-DAS for lupus, RAPID3 PRO across all) and adjusting therapy until remission or low disease activity is reached. AI helps by (1) auto-calculating the score from intake PROs (RAPID3, MDHAQ, BASDAI patient form) + tender / swollen joint count + CRP / ESR, (2) flagging patients above target for visit-day medication-change discussion, (3) generating the T2T letter to the patient + referring PCP, (4) tracking per-patient trajectory in a registry-style dashboard. Tools: RISE Registry (ACR), Bendcare RaaS, Patient IQ, Greenspace Health, Force Therapeutics, Trondent, Smart Sets in Epic / Cerner / athena / eClinicalWorks. The goal is documented T2T at every visit — both an ACR Quality Measure (QPP MIPS Quality ID 177 RA Periodic Assessment) and a payer requirement for premium contracts.

What is the AKS / Stark exposure on in-office infusion + 340B + biologic-buy-and-bill?

Rheumatology infusion suites (Remicade, Actemra, Orencia, Rituxan, Simponi Aria, biosimilars) are a major revenue driver and a major enforcement target. The compliance floor: (1) the buy-and-bill margin must be supported by genuine drug-acquisition + handling cost — no kickback from a wholesaler / GPO / manufacturer disguised as a rebate, (2) the infusion-suite physician-ownership structure must satisfy the in-office ancillary services exception to Stark (42 USC §1395nn) — same-building, supervised, billed under the group, (3) any pharma-funded patient-assistance / co-pay coupon must comply with the OIG Special Advisory Bulletin on patient-assistance programs (no steering Medicare beneficiaries), (4) 340B-covered entities must have a real contract pharmacy + diversion + duplicate-discount controls (HRSA 340B program + Medicaid drug-rebate carve-out), (5) Sunshine Act (Open Payments) reporting on every speaker / consulting / meal / travel item — $13.46 / $134.49 thresholds for FY 2026 reporting. AI can flag every meal log, speaker contract, and 340B claim against the policy — but the compliance officer signs.

What ROI should a 1-5 rheumatologist practice expect from AI in 90 days?

Realistic gains: (1) 35-50% reduction in PA + appeal turnaround time (AI drafts the narrative, payer-policy match, step-therapy override appeal), (2) 8-12 hours per provider per week saved on documentation (ambient scribe + smart-sets), (3) 20-30% lift in T2T documentation rate (auto-scored DAS28 / ASDAS / DAPSA every visit), (4) measurable lift in MIPS MVP MSK quality scores (RA Periodic Assessment, Functional Status, Tobacco Cessation, Influenza, Pneumococcal, BP screening), (5) reduced infusion-suite no-show + missed-dose rate via SMS recall + portal nudges (ACR T2T quality measure), (6) full Sunshine Act + AKS / Stark + 340B audit trail per encounter. The owner monthly scorecard (Prompt 10) is where the dollars actually show up — measured against revenue per visit, infusion-suite utilization, biologic AR, denied-claim turnaround, and MIPS MVP score.

Sources + further reading

Related guides

SharePost on XLinkedIn
—Was this helpful?

Get the best AI tools tips — weekly

Honest reviews, tutorials, and Happycapy tips. No spam.

You might also like

How-To Guide

How to Use AI for a Physical Therapy Practice in 2026: APTA Code of Ethics, Medicare Therapy Cap + KX + Targeted MR, MIPS MVP Rehabilitative Support, State PT Compact, and the Owner Scorecard

14 min

How-To Guide

How to Use AI for a Plumbing Business in 2026: IPC 2024 + UPC 2024 + State Amendments, EPA SDWA + LCRR + LCRI (Oct 8 2024), NSF/ANSI 61 + 372, ASSE Backflow, OSHA Confined Space + Trenching, and the Owner Scorecard

14 min

How-To Guide

How to Use AI for an Estate Planning Law Firm in 2026: ABA Op 512, IRC §2010(c) Sunset Jan 1 2026, UTC + UPC + State Probate, RUFADAA + Slayer + RON, SECURE Act 2.0 + Medicaid + SNT, and the Owner Scorecard

14 min

How-To Guide

How to Use AI for an Infectious Disease Practice in 2026: IDSA/SHEA ASP, Joint Commission MM.09.01.01, CMS CoP §482.42, OPAT, NHSN, Ryan White HRSA RSR, MIPS MVP, and the Owner Scorecard

14 min

Comments